1. Home
  2. HELP vs SLDB Comparison

HELP vs SLDB Comparison

Compare HELP & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cybin Inc. Common Stock

HELP

Cybin Inc. Common Stock

HOLD

Current Price

$6.54

Market Cap

574.7M

Sector

Health Care

ML Signal

HOLD

Logo Solid Biosciences Inc.

SLDB

Solid Biosciences Inc.

SELL

Current Price

$6.46

Market Cap

623.0M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
HELP
SLDB
Founded
2019
2013
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
574.7M
623.0M
IPO Year
2020
2017

Fundamental Metrics

Financial Performance
Metric
HELP
SLDB
Price
$6.54
$6.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
15
Target Price
★ $46.17
$18.71
AVG Volume (30 Days)
★ 1.8M
1.2M
Earning Date
11-16-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 34.97
EPS
★ N/A
N/A
Revenue
N/A
★ $8,094,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$3.76
$4.65
52 Week High
$15.15
$11.45

Technical Indicators

Market Signals
Indicator
HELP
SLDB
Relative Strength Index (RSI) 26.96 46.83
Support Level $4.41 $6.25
Resistance Level $8.50 $6.58
Average True Range (ATR) 0.95 0.50
MACD -0.20 0.02
Stochastic Oscillator 5.76 30.12

Price Performance

Historical Comparison
HELP
SLDB

About HELP Cybin Inc. Common Stock

Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.

About SLDB Solid Biosciences Inc.

Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.

Share on Social Networks: